Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hyperbaric Oxygen Therapy · 1 trial · 3 indications
Self-report questionnaire to assess symptoms of PTSD
A computerized cognitive test to measure various cognitive functions, including memory, executive functioning, visual-spatial perception, verbal function, attention, information processing speed, and motor skills.
Self-report questionnaire to assess depression severity
Self-report questionnaire to measure anxiety severity
Self-report questionnaire to rate a person's perception of his/her position in their life in the context of physical, psychological, level of independence, social relationships, environment, and spirituality/religion/personal belief domains and facets
| Arm | Type | Description |
|---|---|---|
| HBOT Intervention Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Hyperbaric Oxygen Therapy | DRUG | Each HBOT session is scheduled for approximately 95 minutes. The session will begin with a descent of up to 15 minutes (longer if needed for comfort/safety) to a pressure of 2.0 ATA, followed by 30 minutes of breathing 100% oxygen. At the midpoint, there will be a 5-minute air break from oxygen, after which subjects resume breathing 100% oxygen for another 30 minutes. Finally, the session will conclude with an ascent of up to 15 minutes (longer if needed for comfort/safety) back to 1.0 ATA. All sessions are delivered under direct medical supervision with standardized safety protocols. Once approved after medical and behavioral screening, participants complete a battery of cognitive, mental health, and quality of life assessments at baseline (pre-) and after completing the therapy (post-). This arm is distinct from any sham or control interventions because all participants receive the active HBOT treatment. |
Inclusion Criteria: 1. At least 18 years of age. 2. Veteran status 3. Clinically diagnosed with a mTBI, PTSD, Anxiety, or Depression disorder by meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and by a qualified and trained professional. 4. The subject is willing a...
Hyperbaric Oxygen Therapy is being studied for use in TBI Traumatic Brain Injury, specifically to evaluate cognitive function, mental health, and quality of life in affected patients. It is an investigational therapy currently in Phase 2 clinical development for this neurological condition.
Summit Therapeutics Inc. (NASDAQ: SMMT) is developing Hyperbaric Oxygen Therapy for TBI Traumatic Brain Injury. The therapy is currently in Phase 2 clinical development for this neurological indication.
Hyperbaric Oxygen Therapy is in Phase 2 clinical development for TBI Traumatic Brain Injury. It is an investigational therapy and has not yet been approved for this use. One Phase 2 trial is currently recruiting participants.
Hyperbaric Oxygen Therapy is being evaluated in a Phase 2 clinical trial with the identifier NCT07214415. The trial is titled 'Veterans' Cognitive Function, Mental Health, and Quality of Life After Hyperbaric Oxygen Therapy' and is recruiting 54 participants in the United States.
Yes, Hyperbaric Oxygen Therapy is being studied with biomarker-selected patients in its Phase 2 clinical trial for TBI Traumatic Brain Injury. The trial is uncontrolled and does not use randomization or double-blind design.